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Abstract
Cancer is a disease that claims the lives of millions of people every year around the 
world. To date, multiple risk factors that may contribute to its development have been 
described. In recent years, a factor that has been associated to cancer development is 
the presence of bacterial infections that could contribute to its occurrence not only by 
favoring the inflammatory process, but also through the release of proteins that trigger 
tumorigenesis. One of the bacterial species that have recently generated interest due 
to its possible role in cancer development is Salmonella enterica. Nevertheless, for more 
than a decade, attenuated strains of Salmonella enterica have been proposed as a treat-
ment for different neoplasms due to its bacterium tropism for the tumor microenviron-
ment, its oncolytic activity and its ability to activate the innate and adaptive immune 
responses of the host. These two facets of Salmonella enterica are addressed in detail in 
this chapter, allowing us to understand its possible role in cancer development and its 
well-documented antitumor activity.
Keywords: Salmonella, cancer, live-attenuated bacterial vector, tumor selectivity, 
immunotherapy
1. Introduction
In recent years, cancer has become a worldwide public health problem, and millions of people 
die of this disease every year in the world [1]. Despite the efforts made to understand the 
mechanisms involved in carcinogenesis to better develop new therapeutic strategies, the cure 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
for cancer remains unsolved. Among the causes that have been associated with cancer origin 
and development, it is found physical and chemical agents as well as biological processes such 
as inflammation [2], this inflammation has been associated with the presence of infectious bio-
logic agents; these may be viral like human papilloma virus associated to cervical cancer [3], 
or bacterial like Helicobacter pylori in the development of gastric cancer [4], or Escherichia coli 
(E. coli) in the development of colon cancer [5]. In this context, Salmonella enterica has also been 
associated with the development of neoplasms that affecting the gastrointestinal tract such 
as gallbladder cancer [6] and colon cancer [7]. On the other hand, since more than a decade, 
attenuated strains of Salmonella enterica have been evaluated as adjuvants in the treatment of 
different neoplasms [8], including colon cancer [9] due to its great affinity for tumor tissue 
[10, 11], its oncolytic activity and the induction of the innate and adaptive immune response 
against the tumor [12].
The role of Salmonella enterica in cancer is a provocative issue to debate, for that reason, in this 
chapter, we document these two facets of Salmonella enterica as a promoter of the develop-
ment of gastrointestinal tract neoplasms and as a bacterium with antitumor activity and with 
potential use in cancer treatment.
2. Infection by Salmonella enterica and colon cancer
Salmonella enterica genus comprises a wide range of bacteria, including species such as 
Salmonella typhi and Salmonella paratyphi, for which natural host is human and Salmonella 
typhimurium, which has mouse as its natural host [13]. The fact that S. typhimurium causes 
the same type of infection in the mouse than in the human has allowed us to understand in 
great detail the pathogenicity and immunogenicity of these bacteria [14]. Nevertheless, the 
infection by Salmonella enterica has recently begun to be associated with the development of 
neoplasia of the gastrointestinal tract such as colon cancer [7] and gallbladder cancer [6].
The role of Salmonella enterica infection in cancer development is currently under investiga-
tion. Salmonella enterica capacity to modulate host’s inflammatory response [15], contributing 
to neoplasm development has been documented, showing that chronic inflammation induced 
by bacterial infection causes DNA damage and increases cell proliferation and migration, fac-
tors associated with cancer development [16]. Likewise, it has been suggested that at least two 
proteins of Salmonella enterica could trigger the development of colon cancer; the first one, the 
typhoid toxin, a cyclomoduline similar to E. coli CDT protein [17]; which increases cell sur-
vival and is capable of favoring dysbiosis [18], a process known as a risk factor for developing 
inflammatory bowel disease and colon cancer [19]; the second protein of Salmonella enterica 
is the effector protein AvrA, secreted via the type 3 secretion system [20], and that has been 
detected in stool samples obtained from patients with colon cancer [21].
AvrA is a multifunctional protein. On the one hand, AvrA is responsible for decreasing the inflam-
matory response by inhibiting signaling pathways such as the one induced by NF-κB [22] or sup-
pressing the secretion of cytokines such as IL-12, IFN-γ and TNF-α [23] as well as inhibiting IL-6 
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transcription and increasing IL-20 transcription [24]. On the other hand, AvrA would favor tumor 
formation in the intestinal epithelium by activating cell proliferation pathways such as Wnt/β 
catenin pathway [25], associated with colon cancer [26], through two post-translational modifica-
tions, β catenin phosphorylation (activation) and deubiquitination of it (decreasing degradation) 
[7]. Also, AvrA activates Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathway [27], which also plays an important role in carcinogenesis because it is involved in apop-
tosis regulation, cell proliferation and differentiation as well as on the inflammatory response 
[28]. In addition, AvrA has acetyl transferase activity and one of its targets is p53 [29]; when it is 
acetylated, it causes cell cycle arrest and apoptosis inhibition by decreasing proapoptotic proteins 
such as Bax [30]. AvrA mechanisms are summarized in Figure 1.
Figure 1. Oncogenic activity of the Salmonella enterica. Once AvrA is released and internalized via the type 3 secretion system 
of Salmonella enterica, it exerts its oncogenic effect by modulating the following signaling pathways (1) phosphorylation and 
deubiquitination of β catenin, promoting cellular proliferation [7, 25], (2) STAT3 phosphorylation, fostering cell proliferation 
and differentiation as well as decreasing apoptosis [27] and (3) acetylation of the p53 transcription factor that decreases 
apoptosis by transcriptional downregulation of proapoptotic proteins such as Bax [29].
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3. Infection by Salmonella enterica and gallbladder cancer
Gallbladder cancer is the main type of neoplasm that affects the bile ducts. Even though the 
incidences of this neoplasm is low worldwide compared to other types of cancer that affect 
the gastrointestinal tract, the high incidence in some geographic regions like South America 
[31, 32] and Southeast Asia [33, 34] have generated a particular interest on studying the causes 
that contribute to the development of this type of neoplasm on these population.
The main risk factor for developing gallbladder cancer is cholelithiasis, gallstone formation 
(GSD), which favors the inflammatory process and damage to the epithelium [35]. Likewise, 
a second risk factor that has begun to be associated with the development of this neoplasia 
is the infection with Salmonella enterica [33], which enters the gallbladder directly from the 
bloodstream or through the bile [36]. Interestingly, a high incidence of Salmonella enterica has 
been reported in geographic regions where there is a higher number of gallbladder cancer 
cases [6], and several studies have shown its presence in biopsies of patients with gallbladder 
cancer [32, 37–39], where different serotypes of Salmonella enterica such as S. typhi, S. paratyphi, 
S. typhimurium and S. choleraesuis have been found [37].
To date, there is a little information about how an infection with Salmonella enterica would 
participate in the development of gallbladder cancer. One of the main proposed mechanisms 
is the induction of chronic inflammation in the gallbladder [40], which is recurring in patients 
with cholelithiasis [39]. Since Salmonella enterica can go unnoticed for years, and it has the 
ability to form biofilm on gallstones constituted by cholesterol [38]; the inflammation would 
increase immune cell recruitment, including activated macrophages expressing COX-2 [41], 
which is an enzyme that plays a role in the development of tumors in the gastrointestinal tract 
[42, 43]. In addition, the inflammatory process causes alterations in the TP53 gene, increasing 
the risk to develop gallbladder cancer [44]. Lastly, in another study, it was shown that infec-
tion with S. typhimurium in cell lines and gallbladder organoids produces malignant trans-
formations, by activating the MAPK and AKT pathways, which were associated with the 
development of gallbladder tumors in a murine model [6].
According to the data presented earlier, infection with Salmonella enterica could be a factor 
associated with the development of neoplasms in the gastrointestinal tract, where the chronic 
inflammatory process induced by the bacteria, as well as some of its effector proteins would 
be responsible for triggering the tumor process. However, more studies are needed in order 
to better understand the role of Salmonella enterica in carcinogenesis.
4. Antitumor activity of Salmonella enterica
Contrary to carcinogenesis induction, infection by bacteria such as Salmonella enterica facili-
tates the elimination of tumor cells [11]. The use of bacteria and their derivatives to treat 
cancer was first documented by William Coley over a century ago, using “Coley’s Toxin,” a 
compound of Streptococcus pyogenes and Serratia marcescens extract intended for the treatment 
of patients with sarcoma, carcinoma, lymphoma, melanoma and myeloma [45]. Since 1976, 
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subsequent studies led to the use of the attenuated strain of Mycobacterium bovis (Bacillus 
de Calmette-Guérin, BCG) administered intravesically as immunotherapy against superficial 
transitional cell bladder carcinoma [46].
To date, Salmonella enterica is one of the most studied bacteria in the fight against cancer [11]. 
Results of a phase I clinical trial with S. typhimurium strain VNP20009 showed that the bac-
terium does not lead to severe adverse effects and it is well tolerated by patients with meta-
static melanoma, metastatic renal carcinoma, carcinoma of the head and neck and esophageal 
adenocarcinoma [47–49]. The mechanisms implicated in the ability of Salmonella enterica to 
eliminate tumors remain under scrutiny, but its tropism for the tumor microenvironment, its 
oncolytic activity and its ability to activate the innate and adaptive immune responses of the 
host have been documented (Figure 2).
4.1. Tumor selectivity of Salmonella enterica
For over a decade, the use of live-attenuated strains of Salmonella enterica as a therapeutic 
alternative against cancer [8, 11] has been favored by this bacterium’s ability to effectively 
and selectively colonize the tumor microenvironment [8, 12]. Several studies have described 
Figure 2. Salmonella enterica selectivity for the tumor, oncolytic activity and induction of immune response. Once 
Salmonella enterica reaches the tumor tissue, attracted by molecules such as aspartate, serine, ribose/galactose [50, 51] 
and ethanolamine [53], it induces its antitumor oncolytic activity promoting cell death via nitric oxide production [74], 
decreased angiogenesis [78], autophagy activation [79, 80], activation of immunogenic death [81] and activation of the 
innate and adaptive antitumor immune responses [74, 87, 89–91].
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how Salmonella enterica infects and replicates within tumors in murine models in a 1:1000 
ratio compared to normal tissue [10]. Although the mechanisms of tumor selectivity are 
still controversial, in vitro studies mimicking the tumor microenvironment have shown that 
Salmonella enterica migrates to the tumor tissue due to attraction by certain molecules such 
as amino acids and carbohydrates that allow the bacteria to arrive and penetrate the tumor 
tissue and then direct to the necrotic area [50, 51]. In addition, ethanolamine, a molecule 
found in elevated concentrations in different types of neoplasia [52], has also been found to 
act as a chemotactic agent because the deletion of the eutC gene (part of the operon encod-
ing the enzyme ethanolamine-ammonia-lyase (EAL) which metabolizes ethanolamine [53]) in 
Salmonella enterica, decreased its colonization in a murine model of breast cancer [54].
Other studies have referred that Salmonella enterica migration involves motility proteins such 
as the CheA/CheY system [50, 51, 55], proteins fliA, fliC and flgE [56] and the motAB gene, 
the flagellar motor of the bacteria [54]. The Salmonella enterica metabolic pathways of aromatic 
amino acids (aroA) and purines (purA) are also relevant since mutations in these metabolic 
pathways lead to decreased recruitment in tumor tissue [56, 57].
On the other hand, the microenvironment in the tumor characterized by (1) hypoxia [58], 
(2) acidity [59] and (3) necrosis contributes to bacterial proliferation [11]. The permanence of 
Salmonella enterica in tumor tissue may be fostered by low macrophage and neutrophil activ-
ity [60], suppression of the immune response mediated by cytokines such as TGF-β, and the 
difficult access of anti-Salmonella antibodies and factors of the complement pathway due to 
the irregular growth of blood vessels in the tumor [61].
4.2. Oncolytic activity of Salmonella enterica
Several studies have documented the antitumor activity of Salmonella enterica in murine can-
cer models, including lung cancer [62], carcinoma of the colon [57, 63], prostate cancer [64], 
T-cell metastatic lymphoma [65] and B-cell lymphoma [66], among others. In these studies, 
Salmonella enterica inhibited tumor growth and its metastases, while also increasing the lifes-
pan of the mice. These results are consistent with reports in murine models of xenotransplants 
of breast cancer [67] and prostate cancer [68, 69], using auxotrophic strains of S. typhimurium 
such as the A1 strain (deficient in leucine and arginine synthesis) and the A1-R strain (defi-
cient in leucine and arginine synthesis but with a greater capacity to eliminate tumor cells); 
these do not cause any injuries in the host because the bacterium has greater affinity for the 
tumor tissue [67]. Other studies have shown that the A1-R strain inhibits the formation of 
metastases in bone of murine breast cancer models [70] as well as metastases from osteosar-
coma [71], pancreatic cancer [72] and dorsal spinal cord gliomas [73].
Although the mechanisms through which Salmonella enterica induces tumor cell death are 
still under study, some proposed mechanisms involve: (1) apoptosis induction via nitric oxide 
(NO) production [74]: NO, the product of nitrate and nitrite degradation (generated by the 
hypoxic tumor microenvironment) [75] via Salmonella enterica nitrate reductase (NirB) [76], 
could induce the intrinsic apoptotic pathway [77]. (2) Decreased angiogenesis: Salmonella enterica 
inhibits the expression of the transcription factor HIF-1α and thus, the decrease in vascu-
lar endothelial growth factor (VEGF) [78]. (3) Autophagy activation through the AKT/mTOR 
pathway: the presence of Salmonella enterica in the tumor decreases phosphorylation of the 
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proteins AKT and mTOR and increases the expression of Beclin-1 and LC3 (microtubule-
associated protein 1A/1B-light chain 3) [79, 80], thus promoting autophagy. (4) Induction of 
immunogenic cell death (ICD): this type of cell death could be caused by calreticulin (CRT) [81], 
a protein in the endoplasmic reticulum, when secreted by the cell participating in ICD [82], 
which increases due to the presence of Salmonella enterica in tumor tissue. Other mechanisms 
involved in tumor cell elimination and fostered by Salmonella enterica include the induction of 
the innate and adaptive immune response, as described later.
4.3. Activation of the innate antitumor response by Salmonella enterica
The immune response generated against Salmonella enterica once it has entered the host [83, 84] 
plays an important role in tumor recognition due to the recruitment of immune response cells 
in the tumor and its metastases [85, 86]. In the tumor microenvironment, Salmonella enterica 
induces the reversal of the suppressor environment by facilitating the expression of soluble 
mediators such as inducible nitric oxide synthase (iNOS) and interferon-γ (IFN-γ), molecules 
that promote antitumor activity and inhibit the expression of immunosuppressive factors such 
as arginase-1, interleukin-4 (IL-4), transforming growth factor-β (TGF-β) and vascular endo-
thelial growth factor (VEGF) [8, 87]; also, Salmonella enterica decreases the activity of myeloid-
derived suppressor cells (MDSCs) [88] and promotes the recruitment of natural killer (NK) 
cells [89], neutrophils [74], macrophages [87] and T [90] and B lymphocytes [91]. The first 
studies describing the immunotherapeutic antitumor properties of Salmonella enterica were 
reported by Kurashige S. et al.; whereby with the use of mini cells (vesicles with no genomic 
DNA) obtained from S. typhimurium and administered to a murine sarcoma model [92] and 
T-cell lymphoma [93], and macrophage activity was restored in the tumor microenvironment 
and helped eliminate the tumor.
Some studies have documented the ability of Salmonella enterica to induce the activation of 
the inflammasome during the early stages of bacterial colonization, via type NOD receptors 
(NLR) [94], favoring interleukin-1β (IL-1β) and TNF-α activation [95], and increasing the lev-
els of proinflammatory cytokines and decreasing those of anti-inflammatory cytokines [86] 
in the tumor microenvironment. The antitumor efficacy of Salmonella enterica is further pro-
moted by the induction of the immune response via TLR-MYD88 signaling, thus establishing 
that cytokine production and modulation may result from the activation of toll-like receptors 
(TLRs) in the tumor tissue [96].
It is known that bacterial components of Salmonella enterica, such as lipopolysaccharide (LPS), 
flagellin and the CpG sites are recognized by the TLRs, and lead to activation of the signaling 
pathways inducing the innate and adaptive immune responses. In this context, the interac-
tion of the LPS from Salmonella enterica with TLR4 has been shown to contribute to decreased 
tumor growth and to the recruitment of neutrophils and macrophages [97]. Likewise, the 
interaction of Salmonella enterica flagellin with TLR5 prevented the development of metasta-
ses in a murine melanoma model [98]. These results were consistent with the use of a TLR5 
agonist used in a murine lymphoma model in which the antitumor effect was associated to 
the activation of CD8+ lymphocytes and NK cells [99]. Subsequent studies using TLR4 and 
TLR5 knockout (KO) mice have confirmed their role in the antitumor response mediated by 
Salmonella enterica [100].
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The antitumor effects, to which TLRs have been associated, are the recruitment of cells such 
as macrophages, NK cells, T and B lymphocytes, resulting from increased TNF-α level due 
to TLR4 activation by LPS [95, 101]. The increased TNF-α would therefore promote bleeding 
from the blood vessels of the tumor and allow the infiltration by immune response cells [102] 
that would eliminate the tumor cells. Further, the presence of Salmonella enterica in tumor 
tissue increases the amount of immune response cells in the spleen [81], which subsequently 
migrate to the tumor and contribute to its eradication.
4.4. Induction of the antitumor adaptive immune response by Salmonella enterica
Some studies have described that the adaptive immune response induced against Salmonella 
enterica antigens is one of the mechanisms eliminating tumor cells. Tumor cells infected with 
Salmonella enterica and that present these antigens of the bacteria are eliminated by cytotoxic T 
lymphocytes; this has been documented in the elimination of solid and non-solid tumors [85, 89].
Salmonella enterica contributes to the reversal of tumor immune tolerance by decreasing the 
number of Treg lymphocytes (CD4+ CD25+) in tumor tissue [103] due to the effects of LPS 
and the Braun lipoprotein (Lpp) of Salmonella enterica [104], and the decreased levels of indole-
amine 2, 3 dioxygenase 1 (IDO1) (enzyme participating in tryptophan metabolism and asso-
ciated with the development of immune tolerance by T lymphocytes) [105, 106], precluding 
the formation of kynurenine and thus favoring the proliferation of T lymphocytes capable of 
recognizing and eliminating the tumor [79]. Aside from reversing immune tolerance and pro-
moting the recruitment of immune response cells in the tumor microenvironment, Salmonella 
enterica also induces the activation and maturation of T lymphocytes [107], probably as a result 
of the induced overexpression of gap junction proteins such as connexin 43 (Cx43) [108]; this 
protein plays a role in B and T lymphocyte activation [109] as well as in antigen presentation 
to DC [110], thus allowing the transfer of tumor cell preprocessed antigens to DC for their 
adequate presentation by MHC class I [108], thus generating a specific antitumor response.
Studies conducted by Shilling et al. [111] showed that the in vitro activation of DC purified from 
mice, with cytoplasmic fractions of S. typhimurium and with heat shock proteins from tumor 
cells, prevented tumor formation after regrafting. Further, they showed that activated dendritic 
cells tended to preferentially localize in the tumor. These studies were consistent with the reports 
published by Avogadri F et al., which observed that the intravenous administration of Salmonella 
enterica favored cross-presentation of tumor antigens to DC, inducing the activation of CD8+ lym-
phocytes capable of recognizing the tumor [86]. Studies conducted by Grille et al. demonstrated 
that the administration of Salmonella enterica to a murine B-cell lymphoma model induced a local 
and systemic antitumor response, with the recruitment of CD8+ and CD4+ lymphocytes in the 
tumor and the presence of specific antibodies directed against the tumor cells [89].
5. Conclusion
The aforementioned data document the duality of the infection caused by Salmonella enterica, 
in which the chronic inflammation promoted by this bacterium induces DNA injury, and 
some proteins of the bacterium increase cellular proliferation and migration and decrease the 
Salmonella - A Re-emerging Pathogen62
cell death, all these factors are associated with the development of cancer. On the other hand, 
infection with attenuated strains of Salmonella enterica promotes the elimination of tumor cells 
via intrinsic mechanisms that induce an oncolytic effect on the tumor cell while simultane-
ously promoting antitumor innate and adaptive immune responses; it appears to be an excel-
lent candidate as a therapeutic alternative against cancer [8].
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